Transforming Oncology Drug Development Through AI Insights
Lantern Pharma is leveraging A.I., machine learning & genomics to transform the cost, pace, and timeline of oncology drug discovery and development.
A Pioneering & World Class Team Dedicated to
Creating Novel & Breakthrough Precision Oncology Therapies
"We are in the golden
age of A.I. in medicine."
Key Reasons to Watch
Nasdaq: LTRN
Lantern Pharma is an emerging, oncology-focused, clinical stage pharma at the intersection of Artificial Intelligence, Genomics, and Machine Learning.
Breakthrough Cancer Drug Pipeline: Advancing five clinical-stage drug candidates targeting some of the most difficult-to-treat cancers, with multiple ongoing Phase 1 and 2 trials globally.
Proprietary AI Platform, RADR®: Lantern’s AI-driven RADR® platform leverages over 100 billion datapoints to accelerate drug discovery by 70% and reduce development costs by 80%, with predictive accuracy of 88% in patient stratification.
FDA Fast Track & Rare Disease Designations: Received multiple FDA designations, including Fast Track for LP-184 in Glioblastoma and Triple Negative Breast Cancer, and rare pediatric disease designations for three childhood cancers.
Strong Clinical Momentum & Global Expansion: Early clinical data shows an 86% clinical benefit rate in the Harmonic™ Phase 2 trial; expanded trials across the US, Taiwan, and Japan with APAC patient enrollment underway.
Strategic Collaborations & Monetization Pathways: Collaborations with leading research institutions like Bielefeld University and efforts to commercialize the RADR® AI platform and Starlight Therapeutics create multiple revenue opportunities beyond drug development.
Fill Out The Form Below To Receive The Most Up-To-Date Information on This Exciting Investment Opportunity.
I Consent to Receive SMS Notifications, Alerts, Occasional Marketing Communication from Lantern Pharma, InvestorHyve, or their affiliates and my data may be used for profiling. Message frequency varies. Message & data rates may apply. You can reply STOP to unsubscribe at any time.
Who is Lantern Pharma?
Lantern Pharma (Nasdaq:LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its RADR® platform leverages artificial intelligence and machine learning to uncover novel therapeutic opportunities, accelerate drug development, and improve patient outcomes.
Lantern’s AI platform, RADR, is transforming the cost, pace, and timeline of cancer drug discovery and development
12 Lead drug programs* powered by AI
5 Clinical stage lead drug candidates*
100+ Issued patents and pending applications
$100M Approximate total capital raised since 2019
2.5yrs Avg. time for new LTRN programs for Ph.1 Trial
2M Avg. cost for new LTRN programs for Ph.1 Trial
* Includes drug programs being developed in collaboration
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
July 15, 2025
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR® platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, growing at a CAGR of 8.5%, this module represents a significant advancement in precision oncology, enabling faster, more cost-effective development of tailored therapeutic regimens. Leveraging this AI-driven framework, Lantern Pharma has successfully architected and achieved FDA clearance for a Phase 1B/2 clinical trial in triple-negative breast cancer (TNBC), focusing on a novel DDA-DDRi combination regimen with promising preclinical efficacy.....
Lantern’s AI-Driven Business Model has Multiple Routes Towards Success
Transforming the World of Cancer Treatment
As of July 17
Market Value
Enterprise Value
Price to Earnings
Diluted Earnings Per Share Forward Dividend & Yield
Sector
Industry
LTRN
Lantern Pharma Inc
45.94M
45.94M
--
--
--
Healthcare
Biotechnology
LTRN
Lantern Pharma Inc
45.94M
45.94M
--
--
--
Healthcare
Biotechnology
LTRN
Lantern Pharma Inc
45.94M
45.94M
--
--
--
Healthcare
Biotechnology
LTRN
Lantern Pharma Inc
45.94M
45.94M
--
--
--
Healthcare
Biotechnology
Collaborations
World-Class Academic and Research Institutions
Strategic collaborations that are providing unique real-world insights and accelerating timelines
Biopharma Collaborations
©2025 Immix Biopharma | All Rights Reserved | Privacy Policy | Legal Disclaimer